This Viewpoint discusses the US Food and Drug Administration’s authority to require drug and device sponsors to submit diversity action plans and policy gaps that limit the organization’s ability to achieve demographic representation in clinical trials.

中文翻译：

---

临床试验多样性行动计划的前景和危险


本观点讨论了美国食品和药物管理局要求药物和设备申办者提交多样性行动计划和政策差距的权力，这些差距限制了该组织在临床试验中实现人口代表性的能力。